Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by Dana-Farber Cancer Institute
Sponsor:
Collaborators:
Eisai Inc.
Genentech, Inc.
Information provided by (Responsible Party):
Rachel Freedman, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01912963
First received: July 24, 2013
Last updated: July 6, 2014
Last verified: December 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2021
  Estimated Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)